SEC Form 4 · accession 0001358403-16-000197
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Daly
Director
Period of report
May 17, 2016
Accepted (ET)
May 19, 2016 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.40 | May 17, 2016 | A | 20,000 | A | — | May 16, 2026 | Common Stock | 20,000 | 20,000 | D |
| Stock Option (right to buy)F2 | $9.40 | May 17, 2016 | A | 833 | A | — | May 16, 2026 | Common Stock | 833 | 833 | D |
Explanation of responses
- F1The shares subject to the option vest and become exercisable in 36 equal monthly installments.
- F2The shares subject to the option vest and become exercisable on the date of the Issuer's 2016 annual meeting of stockholders.